Roche Holding stock adds Phase II Alzheimer's trial ahead of CTAD

Roche is expanding its Alzheimer's disease pipeline with a new Phase II study targeting neuroinflammation, adding another clinical catalyst ahead of the Clinical Trials on Alzheimer’s Disease Congress in Boston. The company announced the program on Tuesday, November 10, and will present its broader research portfolio from Monday, November 16, through Thursday, November 19.

Roche Holding stock traded at 437.10 euros on Lang & Schwarz at 11:36 CET on Friday, November 13, 2026.

A new neuroinflammation program

According to Roche, the TARBELA-AD study will evaluate RG6434, an investigational oral inhibitor of the NLRP3 inflammasome, in people with early symptomatic Alzheimer’s disease. The randomized, double-blind and placebo-controlled Phase II trial is designed to assess efficacy and safety while testing neuroinflammation as a therapeutic target alongside amyloid aggregation.

Roche said the program complements its ongoing trontinemab work rather than replacing it. Chief Medical Officer and Head of Global Product Development Levi Garraway described amyloid clearance as an important foundation but said the company is pursuing complementary strategies because Alzheimer’s disease involves multiple biological mechanisms.

CTAD brings several catalysts

Roche plans to present 16 accepted abstracts at CTAD, including two scientific symposia and two oral presentations. The agenda includes updated Phase Ib/IIa Brainshuttle AD data for trontinemab, with research on amyloid removal dynamics, biomarkers and safety.

The company also said its Phase III PrevenTRON study in preclinical Alzheimer’s disease has started enrolling participants. An oral presentation on Wednesday, November 18, will outline the study design and screening of cognitively unimpaired individuals with Alzheimer’s biomarkers who face a high risk of clinical decline.

RG6434 will receive a dedicated focus during the congress. Roche is scheduled to present early Phase I safety data in healthy participants and the rationale and design of TARBELA-AD. The neuroinflammation symposium is set for Tuesday, November 17, while the trial-design poster will be available from Monday, November 16.

Diagnostics add another growth angle

Roche’s CTAD program also covers its diagnostics division. The company plans to present clinical, health-economic and real-world research on the Elecsys pTau217 and pTau181 blood tests, including work on integrating blood-based biomarkers into routine care and improving diagnostic pathways.

Roche says Elecsys pTau217 is the first and only FDA-cleared single-biomarker blood test that can both rule in and rule out amyloid pathology. The diagnostic portfolio gives investors a second route to Alzheimer’s exposure, alongside the higher-risk development pipeline for investigational medicines.

Investors await clinical evidence

The CTAD presentations are expected to provide further detail on the design, biological rationale and early evidence behind Roche’s Alzheimer’s programs. TARBELA-AD remains an investigational study, so its eventual investment significance will depend on clinical execution and later efficacy results rather than the announcement alone.

The broader Swiss equity market can be followed through current SMI market coverage.

More news and analyses on Roche Holding stock will track the company’s clinical and diagnostic developments.